Russian MedicineRussian MedicineРоссийский медицинский журнал0869-21062412-9100Eco-Vector67800210.17816/medjrf678002WDBZMOReviewsНаучные обзорыReview ArticleTargeted therapy in older adults with Alzheimer disease: a reviewТаргетная терапия у пожилых пациентов с болезнью Альцгеймера: литературный обзорhttps://orcid.org/0009-0002-2633-75018752-4164BulinaPolina A.БулинаПолина Алексеевна
Russian Federation
pollybulina@mail.ruhttps://orcid.org/0009-0003-1947-1443PopovaPolina A.ПоповаПолина Анатольевна
Russian Federation
apolinaria_2002@mail.ruhttps://orcid.org/0009-0000-7558-4555DyatchinaLyubov S.ДятчинаЛюбовь Сергеевна
Russian Federation
lyubov.dyatchina@mail.ruhttps://orcid.org/0009-0000-3798-3600GoliatinaMariia M.ГолятинаМария Михайловна
Russian Federation
padalekimary@mail.ruhttps://orcid.org/0009-0001-0131-025XZaitsevaAnastasia P.ЗайцеваАнастасия Павловна
Russian Federation
super.z-nastia@ya.ruhttps://orcid.org/0009-0005-8777-1055AbramenkoAnastasiia A.АбраменкоАнастасия Александровна
Russian Federation
nabramenko32@gmail.comhttps://orcid.org/0000-0002-9939-34439133-3802RaevskiiKirill P.РаевскийКирилл Павлович
Russian Federation
raevskiikp@my.msu.ruNorth-Western State Medical University named after I.I. MechnikovСеверо-Западный государственный медицинский университет имени И.И. МечниковаSaint-Petersburg State Pediatric Medical UniversityСанкт-Петербургский государственный педиатрический медицинский университетAcademician I.P. Pavlov First St. Petersburg State Medical UniversityПервый Санкт-Петербургский государственный медицинский университет имени академика И.П. ПавловаLomonosov Moscow State UniversityМосковский государственный университет имени М.В. Ломоносова18062025041120253154935000404202505062025Copyright ©; 2025, Eco-VectorCopyright ©; 2025, Эко-Вектор2025Eco-VectorЭко-Векторhttps://medjrf.com/0869-2106/article/view/678002

One of the most pressing issues today is the somatic and mental health of older adults due to increasing life expectancy and expanding diagnostic capabilities for various diseases.

Alzheimer disease has a significant impact on the quality of life of patients and their families and results in substantial economic and social consequences for society. Patients with Alzheimer disease require continuous care and support, which demands considerable resources from health care and social service systems. Moreover, Alzheimer disease leads to reduced work productivity and increased health care expenditures.

This review analyzes foreign and Russian articles published in the past 5 years in Scopus, PubMed Central, the Cochrane Library, and BMJ Case Reports regarding targeted therapy for Alzheimer disease, one of the most common neurodegenerative disorders that reduce quality of life. This review considers the main principles of targeted therapy used in older adults with Alzheimer disease are considered, along with its advantages, limitations, and future perspectives for this therapeutic approach.

Одной из наиболее актуальных проблем в настоящее время является соматическое и психическое здоровье старшего поколения ввиду увеличения продолжительности жизни и расширения возможностей в сфере диагностики тех или иных заболеваний.

Болезнь Альцгеймера оказывает значительное влияние на качество жизни пациентов и их семей, а также создаёт серьёзные экономические и социальные последствия для общества. Пациенты с болезнью Альцгеймера нуждаются в постоянном уходе и поддержке, что требует значительных ресурсов системы здравоохранения и социальных служб. Кроме того, болезнь Альцгеймера приводит к снижению производительности труда и увеличению расходов на медицинское обслуживание.

В данном обзоре проанализированы зарубежные и отечественные статьи из баз данных Scopus, Pubmed Central, Cochrane Library и BMJ Case Reports за последние 5 лет на тему таргетной терапии болезни Альцгеймера как одного из самых распространённых нейродегенеративных заболеваний, снижающих качество жизни. Рассмотрены основные принципы таргетной терапии, используемой при болезни Альцгеймера у пожилых пациентов, её преимущества и ограничения, а также перспективы развития этого направления в будущем.

Alzheimer diseasetargeted therapymemantineamyloid cascade hypothesislecanemabболезнь Альцгеймератаргетная терапиямемантинтеория амилоидного каскадалеканемабTkacheva ON, Frolova EV, Yakhno NN, editors. Geriatrics. Moscow: GEOTAR-Media; 2019. (In Russ.)Alzheimer’s Disease International. Long S, editor. World Alzheimer Report 2023: Reducing dementia risk: never too early, never too late. Available at: https://www.alzint.org/u/World-Alzheimer-Report-2023.pdfMelnikov AM, Popugailo MV. Analysis of the pharmaceutical market of drugs for the treatment of Alzheimer's disease. Sovremennye problemy zdravoohranenija i medicinskoj statistiki. 2022;(5):94–106. doi: 10.24412/2312-2935-2022-5-94-106 EDN: WNEJBYNasaeva ED, Khasanova EM, Gankovskaya LV. Immunopathogenesis and target therapy of Alzheimer’s disease. Immunologiya. 2023;44(2):231–242. doi: 10.33029/0206-4952-2023-44-2-231-242 EDN: RNKUGOVolobuyev A, Romanchuk P, Romanchuk N, et al. Polymorphism of the apoe gene: prevalence of phenotypes in the population and an association with the development of Alzheimer's disease. Vrach. 2023;34(6):73–75. doi: 10.29296/25877305 EDN: SJQFDGLitvinenko IV, Emelin AYu, Lobzin VYu, et al. The amyloid hypothesis of alzheimer's disease: past and present, hopes and disappointments. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3):4–10. doi: 10.14412/2074-2711-2019-3-4-10 EDN: WGKGKANikolaeva NS, Yandulova EY, Aleksandrova YR, et al. The role of a pathological interaction between β-amyloid and mitochondria in the occurrence and development of Alzheimer's disease. Acta Naturae. 2022;14(3):19–34. doi: 10.32607/actanaturae.11723 EDN: MMRSJDAbdullayeva N, Aliyeva G. The relationship of tau-protein with the pathology of Alzheimer’S disease. Norwegian Journal of Development of the International Science. 2021;63-1:9–12. doi: 10.24412/3453-9875-2021-63-1-9-12 EDN: FIOIBCSoibnazarov OJe. The role of immunological factors in the pathogenesis of Alzheimer’s disease. Research Focus International Scientific Journal. 2023;2(12):132–139. doi: 10.5281/zenodo.10406458Mamchur AA, Erema VV, Kashtanova DA, et al. Molecular dynamics simulation of the conformational mobility of the lipid-binding site in the apolipoprotein E isoforms Ε2, Ε3, and Ε4. Vestnik Moskovskogo Universiteta. Seriya 16. Biologiya. 2023;78(2):70–77. doi: 10.55959/MSU0137-0952-16-78-2-3 EDN: HATRJQPreobrazhenskaya IS, Snitskaya NS. The development and treatment of Alzheimer’s disease: Some genetic aspects. Neurology, Neuropsychiatry, Psychosomatics. 2014;6(4):51–58. doi: 10.14412/2074-2711-2014-4-51-58Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535–562. doi: 10.1016/j.jalz.2018.02.018Leuzy A, Mattsson-Carlgren N, Palmqvist S, et al. Blood-based biomarkers for Alzheimer's disease. EMBO Mol Med. 2022;14(1):e14408. doi: 10.15252/emmm.202114408 EDN: TAFZISGuzmán-Martínez L, Tapia JP, Farías GA, et al. The Alz-tau biomarker for Alzheimer's Disease: Study in a Caucasian population. J Alzheimers Dis. 2019;67(4):1181–1186. doi: 10.3233/JAD-180637Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024;20(8):5143–5169. doi: 10.1002/alz.13859 EDN: SAWTALDubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol. 2021;20(6):484–496. doi: 10.1016/S1474-4422(21)00066-1 EDN: SIIFOMKotsenko YuI, Nesterov VS. Modern methods for early diagnosis of Alzheimer’s disease. Universiti Clinic. 2024;(2):77-82. EDN: EUWPFMTwarowski B, Herbet M. Inflammatory processes in Alzheimer's Disease — Pathomechanism, diagnosis and treatment: A review. Int J Mol Sci. 2023;24(7):6518. doi: 10.3390/ijms24076518 EDN: YKFCDDBeata BK, Wojciech J, Johannes K, et al. Alzheimer's disease — biochemical and psychological background for diagnosis and treatment. Int J Mol Sci. 2023;24(2):1059. doi: 10.3390/ijms24021059 EDN: ISLDBJDubois B, von Arnim CAF, Burnie N, et al. Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants. Alzheimers Res Ther. 2023;15(1):175. doi: 10.1186/s13195-023-01314-6 EDN: NVCPMKRajput S, Malviya R, Bahadur S, Puri D. Recent updates on the development of therapeutics for the targeted treatment of Alzheimer's disease. Curr Pharm Des. 2023;29(35):2802–2813. doi: 10.2174/0113816128274618231105173031 EDN: DOTZMAToader C, Dobrin N, Brehar FM, et al. From recognition to remedy: The significance of biomarkers in neurodegenerative disease pathology. Int J Mol Sci. 2023;24(22):16119. doi: 10.3390/ijms242216119 EDN: ROUTMWNicoll JAR, Buckland GR, Harrison CH, et al. Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease. Brain. 2019;142(7):2113–2126. doi: 10.1093/brain/awz142Monteiro AR, Barbosa DJ, Remião F, Silva R. Alzheimer's disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochem Pharmacol. 2023;211:115522. doi: 10.1016/j.bcp.2023.115522 EDN: UFIHRAHassan NA, Alshamari AK, Hassan AA, et al. Advances on therapeutic strategies for Alzheimer's disease: From medicinal plant to nanotechnology. Molecules. 2022;27(15):4839. doi: 10.3390/molecules27154839 EDN: TFSHEHGhisays V, Lopera F, Goradia DD, et al. PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriers. Neuroimage Clin. 2021;31:102749. doi: 10.1016/j.nicl.2021.102749 EDN: SJUNNISu IJ, Chang HY, Wang HC, Tsai KJ. A curcumin analog exhibits multiple biologic effects on the pathogenesis of Alzheimer's disease and improves behavior, inflammation, and β-amyloid accumulation in a mouse model. Int J Mol Sci. 2020;21(15):5459. doi: 10.3390/ijms21155459 EDN: DOQTEYDolton MJ, Chesterman A, Moein A, et al. Safety, tolerability, and pharmacokinetics of high-volume subcutaneous Crenezumab, with and without recombinant human hyaluronidase in healthy volunteers. Clin Pharmacol Ther. 2021;110(5):1337–1348. doi: 10.1002/cpt.2385 EDN: NQRYLCVenegas C, Heneka MT. Inflammasome-mediated innate immunity in Alzheimer's disease. FASEB J. 2019;33(12):13075–13084. doi: 10.1096/fj.201900439Garanina EE, Martynova EV, Ivanov KY, et al. Inflammasomes: role in disease pathogenesis and therapeutic potential. Uchenye zapiski Kazanskogo Universiteta. Seriya Estestvennye nauki. 2020;162(1):80–111. doi: 10.26907/2542-064X.2020.1.80-111 EDN: CFDRQFKuwar R, Rolfe A, Di L, et al. A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury. J Neuroinflammation. 2019;16(1):81. doi: 10.1186/s12974-019-1471-y EDN: AJZKNZIwatsubo T. Molecular pathogenesis and disease-modifying therapies of Alzheimer's disease and related disorders. JMA J. 2022;5(3):307–313. doi: 10.31662/jmaj.2022-0079 EDN: QSDZYIVandeVrede L, Gibbs DM, Koestler M, et al. Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab. Alzheimers Dement (Amst). 2020;12(1):e12101. doi: 10.1002/dad2.12101 EDN: NUJFGMVorobev SV, Emelin AYu, Yanishevskij SN. The evolution of ideas about the treatment of Alzheimer’s disease: from the past to the present day. Russian Neurological Journal. 2022;27(1):5–15. doi: 10.30629/2658-7947-2022-27-1-5-15 EDN: FHDDKLLivingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–446. doi: 10.1016/S0140-6736(20)30367-6 EDN: VAADCCCummings J, Zhou Y, Lee G, et al. Alzheimer's disease drug development pipeline: 2024. Alzheimers Dement (N Y). 2024;10(2):e12465. doi: 10.1002/trc2.12465 EDN: SSQWOIBittar A, Bhatt N, Kayed R. Advances and considerations in AD tau-targeted immunotherapy. Neurobiol Dis. 2020;134:104707. doi: 10.1016/j.nbd.2019.104707 EDN: WSNFUNCongdon EE, Ji C, Tetlow AM, et al. Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol. 2023;19(12):715–736. doi: 10.1038/s41582-023-00883-2 EDN: JVSQMFYu TW, Lane HY, Lin CH. Novel therapeutic approaches for Alzheimer's disease: An updated review. Int J Mol Sci. 2021;22(15):8208. doi: 10.3390/ijms22158208 EDN: YWNFDHCummings J, Lee G, Zhong K, et al. Alzheimer's disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021;7(1):e12179. doi: 10.1002/trc2.12179 EDN: SEQCORHamano T, Enomoto S, Shirafuji N, et al. Autophagy and tau protein. Int J Mol Sci. 2021;22(14):7475. doi: 10.3390/ijms22147475 EDN: PASCDG